|Articles|May 18, 2016

ERT Integrates Asthma Measurement Device

ERT announces it has successfully integrated the fractional exhaled Nitric Oxide (FeNO) measurement device by Aerocrine, a Circassia subsidiary, into it’s diagnostic platform for spirometry, ECG and home monitoring for centralized clinical trials.
ERT has integrated Circassia’s fractional exhaled Nitric Oxide (FeNO) measurement device into its MasterScope diagnostic platform, and is available for clinical trials. The device assists clinicians in evaluating and comparing allergic airway inflammations in patients with underlying asthma.
Read the full release here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!

Related Articles

Contact Info

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

IS1
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us